On this page
Key takeaways
• Fisetin has been well tolerated in the Mayo Clinic pulsed protocol (20 mg/kg × 2 days, monthly), which is the safety data most reliably published (3,4).
• Reported minor side effects include mild GI upset, headache, and fatigue — usually self-limiting and dose-related (5,9).
• No serious adverse events specifically attributable to fisetin have been reported in the completed trial cohorts to date (3).
• Long-term continuous daily dosing at commercial capsule strengths has not been formally characterised for safety. Absence of concerning signals is not the same as evidence of long-term safety.
• Fisetin should be avoided in pregnancy, breastfeeding, and children without clinician supervision, and used with caution in patients on anticoagulants, antiplatelet drugs, or CYP2C8-metabolised medications.
• Fisetin is not a substitute for prescribed pharmacotherapy in any serious medical condition, and patients with active cancer should not start fisetin without oncology guidance.
Quick answer
Fisetin has a reassuring general safety profile at the pulsed doses used in the Mayo Clinic trials. Mild GI upset, headache, and fatigue are the most common minor side effects. No serious adverse events have been reported in the completed COVID-FIS cohort of frail older adults — an unusually vulnerable population (3). The long-term safety of continuous daily dosing at 400–800 mg per day over months or years has not been evaluated in any published controlled trial; this is a data gap, not a documented risk. Fisetin should be used with caution in specific populations: pregnancy, breastfeeding, children, patients on anticoagulants or antiplatelet drugs, patients on CYP2C8-metabolised medications, and patients with active malignancy. For the full context, see our complete clinician’s guide.
The overall safety picture
The safety record for fisetin comes from three sources: mechanistic and animal toxicology, the Mayo Clinic clinical trials, and the accumulated post-marketing experience of consumers taking commercial capsule products over the past decade.
- Toxicology. Fisetin has been evaluated in standard toxicology assays and shown a favourable profile. It has GRAS (Generally Recognized As Safe) designation in some food applications. Acute high-dose oral toxicity in animal models occurs only at doses far above human supplemental exposure (5,6).
- Clinical trials. The completed COVID-FIS trial (NCT04537299) enrolled nursing home residents with SARS-CoV-2 infection — a population unusually vulnerable to adverse drug effects — and reported a favourable safety profile at 20 mg/kg × 2 days (3). The COVFIS-HOME community trial, the ongoing AFFIRM Phase 2 trial, and the OA cartilage trial share the same protocol architecture and, to the extent registry updates have appeared, share the same favourable early safety observations (4).
- Consumer experience. Fisetin has been sold as a supplement in most major markets since roughly 2016. Post-marketing reports of serious adverse events are sparse. This does not prove long-term safety — flavonoid supplements are not subject to systematic pharmacovigilance in the way that prescription drugs are — but it is consistent with the trial and toxicology data.
Common minor side effects
The most commonly reported minor side effects are what one might expect from a fat-soluble flavonoid taken at supplemental doses.
Gastrointestinal upset
Mild nausea, cramping, or loose stools have been described — particularly with high single doses on an empty stomach or with poor-quality capsule products. This is a general flavonoid effect rather than a fisetin-specific one, and it is usually self-limiting. Taking fisetin with a fat-containing meal reduces both the GI symptoms and the poor absorption they signal. See our how and when to take fisetin article for the practical detail.
Headache
A minority of readers report mild headache in the hours after a high-dose pulse. The mechanism is not established. It may reflect transient vasoactive effects, mild dehydration, or a general acute stress response to a large flavonoid load. Symptoms are usually mild and self-limiting; taking the dose with adequate water and a fatty meal helps.
Fatigue and mild sedation
Anecdotal reports describe mild fatigue or drowsiness in the hours after fisetin dosing. Some flavonoids have documented activity on GABAergic neurotransmission, and fisetin may share this profile. If you experience this effect, take fisetin in the morning rather than at night, and avoid taking it before activities requiring alertness.
Sleep disturbance
Both directions have been anecdotally reported — some readers describe improved sleep quality, others describe disturbed or lighter sleep. Neither has been formally studied. If you experience sleep changes after starting fisetin, adjusting the time of day is the simplest intervention.
Rare but reported concerns
Skin flushing or rash
Isolated reports of transient skin flushing or mild rash exist. Fisetin is a flavonoid and — like other polyphenols — may act as an allergen in a very small minority of individuals. If a rash develops, discontinue and consult a clinician.
Mild hypotension
Some flavonoids have mild vasorelaxant effects. Fisetin has not been formally studied for blood pressure changes in a controlled trial, but rare anecdotal reports of mild lightheadedness after high-dose pulses are consistent with modest transient hypotension. Our dedicated blood pressure article covers this in detail.
Palpitations
Very rare. When reported, the differential includes anxiety, caffeine consumption, and the mild flavonoid effects noted above. Not established as a fisetin-specific effect.
Fisetin and cancer — a nuanced conversation
This question comes up in both directions and deserves an honest answer.
Does fisetin cause cancer?
There is no evidence that fisetin is carcinogenic. Preclinical data across many cancer models show anti-cancer activity via multiple mechanisms — induction of apoptosis, cell cycle arrest, suppression of angiogenesis, senolytic clearance of tumour-associated senescent cells (7,9). The compound has been extensively studied for potential anti-tumour applications. Nothing in the current literature supports a cancer-promoting concern.
Can fisetin treat cancer?
Preclinically, there is substantial evidence of activity against breast, prostate, lung, colorectal, and other cancer models (7). Clinically, no human oncology trial has demonstrated that oral fisetin at supplement doses affects cancer outcomes. This is important: fisetin is not a treatment for cancer, and it should not substitute for prescribed oncology care.
Cautions in active malignancy
Patients with an active cancer should not start fisetin without explicit oncology guidance. Three specific concerns apply. First, the senolytic mechanism is mechanistically adjacent to cytotoxic activity, and interactions with chemotherapy, targeted therapy, or immunotherapy are not well characterised. Second, fisetin’s CYP2C8 activity may affect the metabolism of some anti-cancer drugs — our drug interactions article covers this. Third, some preclinical work has explored fisetin as a chemosensitiser, meaning it may amplify the effects of concurrent chemotherapy — which could be beneficial or harmful depending on the specific regimen.
Fisetin and immune function
Fisetin has anti-inflammatory activity across a wide range of cell and animal models. In healthy adults, this manifests as modest suppression of NF-κB signalling and reduced production of pro-inflammatory cytokines. There is no evidence that fisetin at supplement doses meaningfully suppresses the general immune response in a healthy adult, and the COVID-FIS trial specifically tested fisetin in acute infection with no immune-suppression signal (3).
For patients with autoimmune conditions or on immunosuppressive therapy, fisetin’s modest anti-inflammatory activity is unlikely to be clinically consequential, but formal interaction studies with immunosuppressants (tacrolimus, mycophenolate, biologics) have not been performed.
The high-dose acute concern
Fisetin appears to be safe in the pulsed protocol at 20 mg/kg × 2 days (approximately 1,400 mg per day for a 70 kg adult). Extending this to a single much higher dose — for example, 4,000 or 5,000 mg in a single administration — has not been formally studied and is not recommended. The absorption ceiling means that doubling or tripling the dose does not proportionally improve the plasma peak, so there is no efficacy incentive to push beyond the trial dose.
Who should avoid fisetin
The following populations should not take fisetin without medical supervision.
• Pregnant or breastfeeding individuals — no safety data at supplement doses. Ordinary dietary intake from strawberries is presumably safe; concentrated capsules have not been studied. See our pregnancy article.
• Children and adolescents — fisetin capsules are formulated for adult use. Ordinary dietary intake from fruits is safe; supplement doses are not appropriate for children.
• Patients on warfarin, DOACs, or antiplatelet drugs — additive bleeding risk is theoretically possible. Clear with prescriber before starting.
• Patients on tyrosine kinase inhibitors or CYP2C8-metabolised medications — the Mayo Clinic protocol specifically excludes these. Clear with prescriber.
• Patients with active cancer — clear with oncology team. Fisetin is not a cancer treatment and interactions with anti-cancer therapy are not characterised.
• Patients scheduled for surgery — stop fisetin at least seven days before elective surgery to minimise theoretical antiplatelet effects, consistent with general polyphenol supplement advice.
• Patients with known flavonoid or polyphenol allergies — avoid.
What we still don't know
• Long-term safety of continuous daily dosing at 400–800 mg per day over months or years has not been characterised in any published controlled trial.
• Effects of chronic fisetin exposure on hepatic function — flavonoids in general are generally hepatoprotective at moderate doses but can produce hepatotoxicity at very high sustained doses. Fisetin-specific human data are absent.
• Whether fisetin at supplement doses affects fertility, sperm parameters, or menstrual cycle regularity — no human data.
• Whether specific patient subgroups (older adults, those with renal or hepatic impairment) are at elevated risk of adverse effects. Not formally studied.
• How fisetin interacts with commonly prescribed cardiovascular medications (statins, beta blockers, ACE inhibitors) at typical doses. Not characterised.
Bottom line
Fisetin has a reassuring safety record for the short pulsed dosing used in the Mayo Clinic trials, with mild self-limiting GI upset, headache, and fatigue as the most common side effects. Long-term continuous daily dosing has not been characterised for safety — this is a data gap, not a documented risk, but it should shape how readers approach chronic supplementation. Pregnancy, breastfeeding, active cancer, concurrent anticoagulation, and CYP2C8-metabolised medications are the specific populations requiring caution. Fisetin should never substitute for prescribed pharmacotherapy in any serious medical condition. For the broader clinical context, see our complete clinician’s guide and drug interactions article.
Frequently asked questions
Is fisetin safe to take long-term?
Short-term safety in the pulsed protocol is well established. Long-term continuous daily dosing safety has not been formally characterised in any published trial. The absence of concerning signals in consumer use over several years is reassuring but not conclusive.
What are the most common side effects?
Mild GI upset, headache, and fatigue. Usually self-limiting. Taking fisetin with a fat-containing meal and in the morning reduces both the frequency and severity.
Can fisetin cause insomnia?
Both directions have been anecdotally reported — some readers describe better sleep, others describe disturbed sleep. Neither has been formally studied. Morning dosing avoids sleep interference.
Does fisetin cause weight loss or gain?
Neither is a documented effect. Some preclinical data suggest metabolic benefits (improved insulin sensitivity, reduced hepatic gluconeogenesis) but no human trial has measured weight change with fisetin supplementation.
Is fisetin safe with alcohol?
No specific interaction has been reported. Both are metabolised by the liver, and moderate concurrent consumption is not clearly problematic. Very high alcohol intake combined with high-dose fisetin has not been studied.
Should I stop fisetin before surgery?
Yes, at least seven days before any elective surgery, as a precaution consistent with general polyphenol supplement advice — flavonoids may have modest antiplatelet effects.
Can I take fisetin if I have kidney disease?
Preclinical data suggest fisetin may be protective against acute kidney injury (8), but no clinical trial has tested fisetin in patients with established chronic kidney disease. Discuss with your nephrologist before starting.
Is fisetin safe for people over 70?
The COVID-FIS trial specifically enrolled older nursing home residents (many over 80) with acute illness and reported a favourable safety profile (3). This is the most encouraging safety data for older adults. Continuous daily dosing in this population still lacks long-term data.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
3. Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: senolytic trials in the COVID era. J Am Geriatr Soc. 2021;69(11):3023-3033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8447437/
4. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
5. Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151-162. https://pmc.ncbi.nlm.nih.gov/articles/PMC3689181/
6. Grynkiewicz G, Demchuk OM. New perspectives for fisetin. Front Chem. 2019;7:697. https://pmc.ncbi.nlm.nih.gov/articles/PMC6817492/
7. Pal HC, Pearlman RL, Afaq F. Fisetin and its role in chronic diseases. Adv Exp Med Biol. 2016;928:213-244. https://pubmed.ncbi.nlm.nih.gov/27671818/
8. Ren Q, Guo F, Tao S, et al. Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice. Biomed Pharmacother. 2020;122:109772. https://pubmed.ncbi.nlm.nih.gov/31918290/
9. Talebi M, Talebi M, Farkhondeh T, et al. New insights into the role of fisetin’s therapeutic effects on cancers, inflammation, and neurodegeneration. Nutr Neurosci. 2022;25(11):2317-2333. https://pubmed.ncbi.nlm.nih.gov/34281485/
10. Niedernhofer LJ, Robbins PD. Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mech Ageing Dev. 2024;220:111995. https://doi.org/10.1016/j.mad.2024.111995